EVOMMUNE INC

Historical 13F Holders

Symbol
EVMN
CUSIP
30054Y107
All holders as of
Q2 2026
Type
Equity
Class
COM SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 30054Y107 since 12/18/2024, newest first.

Filer % of Class Filed
Andera Partners 13G/A Amendment 1
3.9% 8/14/2026
Event 6/30/2026
Price T Rowe Associates Inc /MD/ 13G 5.4% 8/14/2026
Event 6/30/2026
Point72 Asset Management, L.P. 13G
5.3% 7/16/2026
Event 7/15/2026
LSP 7 Cooperative UA 13D/A Amendment 1
14.7% 2/19/2026
Event 2/12/2026
RA Capital Management, L.P. 13D/A Amendment 1
9.7% 2/17/2026
Event 2/12/2026
Pivotal bioVenture Partners Fund I, L.P. 13G
10.9% 2/13/2026
Event 12/31/2025
Andera Partners 13G
6.0% 11/17/2025
Event 11/7/2025
RA Capital Management, L.P. 13D
11.0% 11/17/2025
Event 11/7/2025
LSP 7 Cooperative UA 13D
15.7% 11/14/2025
Event 11/7/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 699 $5.77 k
2026 Q2 117 34.8 M $475 M
2026 Q1 85 34.8 M $798 M
2025 Q4 59 27.2 M $466 M